Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
Status:
Completed
Trial end date:
2019-05-20
Target enrollment:
Participant gender:
Summary
This is a Phase 3, long-term open-label extension study to evaluate the safety, tolerability
and efficacy of tofacitinib in subjects with active PsA who have previously participated in
randomized studies of tofacitinib for this indication.
This study will include a sub-study to evaluate the efficacy, safety and tolerability of
tofacitinib 5 mg BID administered as monotherapy after methotrexate withdrawal compared to
tofacitinib 5 mg BID continued in combination with methotrexate. The sub-study will be
available to subjects who have completed at least 24 months of participation in the
open-label extension study and meet eligibility criteria for the sub-study.